Clinical Trials
101 trialsPED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Fudan University
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
ARISTOCRAT
University of Birmingham
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Shenzhen University General Hospital
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
EMBRACE
Ontario Clinical Oncology Group (OCOG)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd.
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
FUDOSE
UNICANCER
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
TROY
Yonsei University
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
WOLF
University of Pittsburgh
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
DutaBCa-1
CHU de Quebec-Universite Laval
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Chinese PLA General Hospital
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
University of Pittsburgh
POST-BIO
Gruppo Oncologico del Nord-Ovest
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
SOUNDTRACK-B
AstraZeneca
MEMMAT
Medical University of Vienna
SELVEDge
University of Miami
Phenix
Centre Hospitalier Universitaire Vaudois
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
University of Pittsburgh
ISABELA
Massachusetts General Hospital
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
Northern Jiangsu People's Hospital
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
Northern Jiangsu People's Hospital
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Cladribine Venetoclax in Monocytic AML
University of Colorado, Denver
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
LATE-R-GEL-23
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc.